Lisata Therapeutics (NASDAQ:LSTA) and Genelux (NASDAQ:GNLX) Head-To-Head Review

Lisata Therapeutics (NASDAQ:LSTA) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Lisata Therapeutics and Genelux”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170,000.00	174.16	-$16.59 million	($1.86)	-1.75
Genelux	$10,000.00	13,676.20	-$32.15 million	($0.85)	-3.59

Lisata Therapeutics has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Lisata Therapeutics and Genelux, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1	2	0	0	1.67
Genelux	1	0	3	0	2.50

Lisata Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 361.54%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 490.16%. Given Genelux’s stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Lisata Therapeutics.

Volatility and Risk

Lisata Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Genelux has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Profitability

This table compares Lisata Therapeutics and Genelux’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Genelux	N/A	-174.55%	-123.65%

Insider & Institutional Ownership

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Lisata Therapeutics beats Genelux on 7 of the 13 factors compared between the two stocks.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.